Lack of inhibitory effects of green tea catechins in 1,2-dimetylhydrazine-induced rat intestinal carcinogenesis model: comparison of the different formulations, administration routes and doses.
Differences in the modifying effects of green tea catechins (GTC) on intestinal carcinogenesis by different formulations, doses and administration routes were investigated in male rats pretreated with 1,2-dimethylhydrazine (DMH). One hundred and eighty nine F344 male rats received subcutaneous injections of DMH at 40 mg/kg body weight twice a week for 3 weeks. Three days after completion of the carcinogen treatment, they were divided into nine groups. Each was administered a different source of 0.1% or 0.01% of GTC (Mitsui Norin Co. (M) or Taiyo Kagaku Co. (T)) either in the diet (D) or the drinking water (W), or basal diet and tap water alone without GTC for 33 weeks and then killed for autopsy. The survival rate tended to be lower with 0.01% MGTC (W) group than in the other groups. In the large intestine, although the multiplicity and/or incidences of adenomas showed tendencies for dose-dependent decrease in all GTC groups, and the average volumes of tumors tended to be decrease dose-dependently in the MGTC (W) and TGTC (W) groups, the multiplicity of carcinomas did not show such a trend, rather being significantly increased in the 0.01% MGTC (D) and 0.1% TGTC (W) groups. In the small intestine, the incidence and the multiplicity of tumors in all GTC treated groups had a tendency to decrease. On the other hand, the volume of tumors was increased with statistical significance in the 0.01% MGTC (W) and 0.1% TGTC (W) groups. Thus it can be concluded that GTC does not exert chemopreventive effects on intestinal carcinogenesis irrespective of its formulation, dose or route of administration.
Hirose
Masao
M
Division of Pathology, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, 158-8501, Tokyo, Japan. m-hirose@nihs.go.jp
Yamaguchi
Tsuyoshi
T
Mizoguchi
Yasumoto
Y
Akagi
Keisuke
K
Futakuchi
Mitsuru
M
Shirai
Tomoyuki
T
D019813:1,2-Dimethylhydrazine / Q000633:toxicity; D000236:Adenoma / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage*; D001835:Body Weight / Q000187:drug effects; D015197:Carcinogenicity Tests; D002273:Carcinogens / Q000633:toxicity; D002392:Catechin / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004333:Drug Administration Routes; D007414:Intestinal Neoplasms / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D007420:Intestine, Large / Q000187:drug effects; D007421:Intestine, Small / Q000187:drug effects; D008297:Male; D051381:Rats; D011916:Rats, Inbred F344; D013662:Tea
D016588:Anticarcinogenic Agents; D002273:Carcinogens; D013662:Tea; D002392:Catechin; D019813:1,2-Dimethylhydrazine